32 results
8-K
EX-99.1
TSVT
2seventy bio Inc
8 May 24
2seventy bio Reports First Quarter Financial Results and Recent Operational Progress
7:09am
include hypotension, hypoxia, hyperbilirubinemia, hypofibrinogenemia, ARDS, atrial fibrillation, hepatocellular injury, metabolic acidosis, pulmonary
8-K
EX-99.1
TSVT
2seventy bio Inc
5 Apr 24
Regulation FD Disclosure
9:22am
, hyperbilirubinemia, hypofibrinogenemia, ARDS, atrial fibrillation, hepatocellular injury, metabolic acidosis, pulmonary edema, coagulopathy, renal failure
8-K
EX-99.1
TSVT
2seventy bio Inc
18 Mar 24
Departure of Directors or Certain Officers
7:04am
), atrial fibrillation, hepatocellular injury, metabolic acidosis, pulmonary edema, multiple organ dysfunction syndrome, and HLH/MAS.
Identify CRS based
8-K
EX-99.1
TSVT
2seventy bio Inc
5 Mar 24
2seventy bio Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Operational Progress
7:03am
), atrial fibrillation, hepatocellular injury, metabolic acidosis, pulmonary edema, multiple organ dysfunction syndrome, and HLH/MAS.
Identify CRS
8-K
EX-99.1
r8sk7eo1
5 Feb 24
Bristol Myers Squibb and 2seventy bio Share Update on U.S. FDA Oncologic Drugs Advisory Committee Meeting for Abecma in Triple-Class Exposed Multiple
7:02am
8-K
EX-99.2
ab8 rrfdptev0su8zz
12 Dec 23
Regulation FD Disclosure
7:25am
8-K
EX-99.1
v1hkbr xag0ykho6y260
20 Nov 23
Other Events
7:20am
8-K
EX-99.1
elha 3hgpy4o
14 Nov 23
2seventy bio Reports Third Quarter Financial Results and Recent Operational Progress
12:00am
8-K
EX-99.1
wiw 7cr6kue
19 May 23
Regulation FD Disclosure
6:07am
8-K
EX-99.1
woc3nzhv
17 Apr 23
Other Events
7:36am
8-K
EX-99.1
7irx90i0 7tah1s
3 Nov 22
Data suggest promising outcomes can be achieved treating patients with suboptimal response after transplant
9:08am
8-K
EX-99.1
wquk0ehq2fg3 zn
7 Sep 22
2seventy bio Announces Plans to Initiate KarMMa-9 Study of Abecma (idecabtagene vicleucel) in Newly Diagnosed Multiple Myeloma Patients
7:04am
8-K
EX-99.1
1wb4dn2tlpfz9uaarx
10 Aug 22
Other Events
12:00am
10-K
f1i91ub7o3hbv 48sq
22 Mar 22
Annual report
7:09am
8-K
EX-99.1
32eov7
14 Dec 21
2seventy bio Presents Data Across Multiple Cell Therapy Programs at ASH 2021 Annual Meeting
7:36am
10-Q
36d4e1uhqb
1 Dec 21
Quarterly report
7:08am
8-K
EX-99.1
c6bvwmxqfk4c8vha9
4 Nov 21
2seventy bio to Present Data from its Portfolio of Oncology Cell Therapies at the 63rd
4:51pm